1336963-99-5

Basic information

• Product Name: N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide
• Synonyms: N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide
• CAS NO: 1336963-99-5
• Molecular Weight: 261.05
• Mol File: 1336963-99-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide(1336963-99-5)
• EPA Substance Registry System: N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide(1336963-99-5)

Safety Data

• Hazardous Substances Data: 1336963-99-5(Hazardous Substances Data)

Upstream product

• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 302-17-0 chloral hydrate 
• 58534-94-4 2-fluoro-3-bromonitrobenzene 
• 1072-85-1 o-fluorobromobenzene 
• 1336963-98-4 3-bromo-2-fluoroaniline hydrochloride 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 

Downstream Products

• 1336964-54-5 7-bromo-8-fluoro-3-methyl-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylic acid 
• 1336964-56-7 methyl 7-bromo-8-fluoro-3-methyl-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate 
• 1336964-58-9 methyl 7-bromo-3-(bromomethyl)-8-fluoro-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate 
• 1336964-59-0 methyl 3-(1,4'-bipiperidin-1'-ylmethyl)-7-bromo-8-fluoro-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate 
• 1337595-91-1 3-(1,4'-bipiperidin-1'-ylmethyl)-7-bromo-8-fluoro-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylic acid 
• 1336960-27-0 3-(1,4'-bipiperidin-1'-ylmethyl)-7-bromo-8-fluoro-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide 
• 1416013-62-1 2-amino-4-bromo-3-fluorobenzoic acid 
• 1698027-17-6 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid 
• 1698024-73-5 1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one 

Relevant articles and documents

Fused pyridone compounds as kinase inhibitors

The invention discloses a fused pyridone compound serving as a kinase inhibitor, and particularly discloses a compound represented by formula (I). The optical isomer and pharmaceutically acceptable salt thereof as well and as application of the compound as KRAS inhibitor.

CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

INHIBITORS OF KRAS G12C MUTANT PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, B R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.